A study by Mass General Brigham found that taking the weight-loss drug semaglutide before bariatric surgery does not lead to ...

Surgeons are removing up to 10 kilograms of excess skin from patients who have lost major amounts of weight, amid a booming interest in body-contouring operations.

In 2024, roughly 5% of Britons had used a GLP-1 drug - yet the ways they affect bodies and lives are still mysterious and ...

Perioperative optimization of nutrition leads to lower risks, better outcomes, and improved quality of life for patients.

Administration of semaglutide before metabolic and bariatric surgery does not confer benefits for overall weight loss, ...

Obesity significantly increases the risk of obstructive sleep apnea (OSA) due to fat accumulation in the neck and abdominal ...

Taking a GLP-1 receptor agonist prior to bariatric surgery may not boost long-term weight loss and metabolic benefits, a ...

Mass General Brigham researchers found that total weight loss did not increase for patients who took semaglutide before ...

Mass General Brigham researchers found that total weight loss did not increase for patients who took semaglutide before having weight loss surgery ...

Mass General Brigham researchers found that total weight loss did not increase for patients who took semaglutide before ...

Amylyx Pharmaceuticals Inc (AMLX) showcases promising clinical developments and a robust cash position, despite challenges in niche markets.

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) Q4 2024 Earnings Call Transcript March 4, 2025 Amylyx Pharmaceuticals, Inc.